Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SVRA
SVRA logo

SVRA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Savara Inc (SVRA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
5.200
1 Day change
-0.67%
52 Week Range
7.000
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Savara Inc (SVRA) does not present a strong buy opportunity for a beginner, long-term investor with $50,000-$100,000 available for investment. The lack of significant financial growth, weak technical indicators, and absence of strong trading signals suggest holding off on investment at this time.

Technical Analysis

The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 22.686, and moving averages are converging, showing no clear trend. Key support and resistance levels are at S1: 5.069 and R1: 6.089. The pre-market price is $5.25, up 6.28%, but this is not supported by strong technical indicators.

Options Data

Bearish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

The high Option Volume Put-Call Ratio (12.23) indicates bearish sentiment, while the Open Interest Put-Call Ratio (1.36) also leans bearish. Implied volatility is high at 102.09, but IV rank and percentile are low, suggesting limited potential for significant price movement.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
4

Positive Catalysts

  • Insider buying has increased by 373.33% over the last month, which is a positive indicator of confidence in the company. Additionally, the company is actively granting stock options and performance units to attract and retain talent.

Neutral/Negative Catalysts

  • The company's financials show no revenue growth, and net income remains negative at -$32.24M, despite a slight YoY improvement. Technical indicators are weak, and options data suggests bearish sentiment. No recent congress trading data or significant analyst upgrades are available.

Financial Performance

In Q4 2025, revenue remained at $0 with no YoY growth. Net income improved slightly by 10.99% YoY to -$32.24M. EPS remained stagnant at -0.13. Gross margin was 0%, indicating no profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating changes or price target updates are available for SVRA, leaving no clear guidance from Wall Street analysts.

Wall Street analysts forecast SVRA stock price to rise
6 Analyst Rating
Wall Street analysts forecast SVRA stock price to rise
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.230
sliders
Low
9
Averages
10.17
High
11
Current: 5.230
sliders
Low
9
Averages
10.17
High
11
Oppenheimer
Mazahir Alimohamed
NULL
to
Outperform
upgrade
$9 -> $11
AI Analysis
2026-04-24
Reason
Oppenheimer
Mazahir Alimohamed
Price Target
$9 -> $11
AI Analysis
2026-04-24
upgrade
NULL
to
Outperform
Reason
Oppenheimer analyst Mazahir Alimohamed assumed coverage of Savara with an Outperform rating with a price target of $11, up from $9. With Priority Review granted to the BLA for molgramostim, an inhaled GM-CSF therapy, Savara's story has shifted toward regulatory execution and commercial positioning, the firm says. Robust data from Phase 3 IMPALA-2 in autoimmune PAP support the BLA package and the firm's view of a high-probability approval story, also given that prior FDA feedback was only CMC-related.
H.C. Wainwright
Andrew Fein
Buy
maintain
$8 -> $10
2025-12-23
Reason
H.C. Wainwright
Andrew Fein
Price Target
$8 -> $10
2025-12-23
maintain
Buy
Reason
H.C. Wainwright analyst Andrew Fein raised the firm's price target on Savara to $10 from $8 and keeps a Buy rating on the shares. The company resubmitted the application for Molbreevi with Fujifilm Diosynth as its drug substance manufacturer, the analyst tells investors in a research note. The firm believes Savara is increasingly well positioned ahead of a potential Molbreevi launch.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for SVRA
Unlock Now

People Also Watch